Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Our novel product pipeline addresses areas of high unmet medical need, with a focus on epilepsy
Read MoreNews
Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021
January 14, 2021
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at AES2020, the Virtual Annual Meeting of the American Epilepsy Society
December 7, 2020
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
November 13, 2020
Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 5, 2020
Product Pipeline
* A physician-led, Phase 2 proof-of-concept study is ongoing to examine XEN007 as an adjunctive treatment in pediatric patients diagnosed with treatment-resistant childhood absence epilepsy (CAE).
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
